Immune biomarker-based enrichment in sepsis trials

Spinetti, Thibaud; Meisel, Christian; Gunten, Stephan von; Schefold, Joerg C.

doi:10.1186/s13054-020-2774-1

Cited by 2 publications

(2 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,[12][13][14][15] Further, mHLA-DR previously served to guide targeted immunological interventions, for example, using immunostimulatory approaches [16][17][18] or via reduction of inhibitory factors. 19 Such biomarker enrichment 20 may allow for identification of which patient might benefit best from a given immunomodulatory intervention. 2,6,7,14 From an epidemiological perspective, coronavirus disease 2019 (COVID-19; severe acquired respiratory syndrome coronavirus-2 [SARS-CoV-2]) patients appear (clinically) well characterized.…”

Section: Glossarymentioning

confidence: 99%

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

Spinetti

Hirzel

Fux

et al. 2020

Anesthesia &Amp; Analgesia

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Glossarymentioning

confidence: 99%

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

Spinetti

Hirzel

Fux

et al. 2020

Anesthesia &Amp; Analgesia

Self Cite

View full text Add to dashboard Cite

show abstract

“…We compared predefined prognostic biomarker levels between the treatment and control groups. We selected biomarkers to evaluate pathologic changes including those of pro-inflammation (IL-6), anti-inflammation (IL-10), endothelial cell injury (angiopoietin-II [AP2]), and sepsis-associated encephalopathy or brain injury (S100b), which potentially are associated with physiologic roles of vitamin C and thiamine (15)(16)(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial

Park

Hwang

et al. 2021

Shock

View full text Add to dashboard Cite

We evaluated the effects of vitamin C and thiamine administration on biomarkers in patients with septic shock. Methods: This was a post-hoc analysis of the Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS) trial, a multicenter, double-blind, randomized controlled trial. Patients were randomized to either a treatment group (intravenous vitamin C and thiamine for 48 h) or a control group. Interleukin (IL)-6, IL-10, angiopoietin-II (AP2), and S100b were assessed at baseline and at 72 h. The primary outcomes were the biomarker levels at 72 h, and the secondary outcome was reduction rate. Results: Forty-five patients were assigned to the treatment group and 52 were assigned to the control group. Baseline biomarker levels and at 72 h were not significantly different between the treatment and the placebo groups. The reduction rates were not significantly different between the two groups. These outcome variables showed fair diagnostic accuracy for predicting 28-day mortality according to the area under the receiver operating characteristic curve. Conclusion: Vitamin C and thiamine administration during the early phase of septic shock did not significantly change prognostic biomarker levels of IL-6, IL-10, AP2, and S100b. Trial registration: NCT, ClinicalTrials.gov NCT03756220, ATESS. Registered 28 November 2018, https://clinicaltrials.gov/ct2/show/NCT03756220.

show abstract

Immune biomarker-based enrichment in sepsis trials

Cited by 2 publications

References 5 publications

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial

Contact Info

Product

Resources

About